Founded immune markers continue to maintain their relevance for scientific decision-building in breast cancer therapy with even extended meanings. Estrogen receptor (ER) degree mustn't only be classified in optimistic or unfavorable. Low ER levels ≤10% of labeled cells must be dealt with in different ways (LoE 1a/A/AGO++). Tumors with very low ER